Login to Your Account



Eye disease firm AGTC sees its way to $50M IPO

By Michael Fitzhugh
Staff Writer

Friday, March 28, 2014
Investors met Applied Genetic Technologies Corp.’s Nasdaq debut Thursday with tepid interest as the clinical-stage developer of treatments for orphan eye diseases moved to raise $50 million through an initial public offering (IPO) priced at $12 per share, $1 below its intended $13 to $15 range.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription